Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Grand View Research | PRODUCT CODE: 1529805

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1529805

China Botulinum Toxin Type A Market Size, Share & Trends Analysis Report By Application, By Gender, By Age, By End-use, And Segment Forecasts, 2024 - 2030

PUBLISHED:
PAGES: 125 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 3500
Printable PDF (5-User License)
USD 4500
Printable PDF (Enterprise License)
USD 6500

Add to Cart

China Botulinum Toxin Type A Market Growth & Trends:

The China botulinum toxin type A market size is anticipated to reach USD 3.6 billion by 2030, registering a CAGR of 18.9% during the forecast period, according to a new report by Grand View Research, Inc. Key factors driving the country's botulinum toxin market are increasing disposable income fueling spending on medical aesthetics, diverse demand channels across genders and age groups, and the development of consumer-centric treatment modalities. The introduction of newer players within the Chinese botulinum toxin type A market paradigm shifted the market share structure; before 2020, only two products had received approval from China's National Medical Product Administration (NMPA).

However, post-2020, several established market players gained product approvals, while several others are in the pipeline. Such developments are expected to create lucrative opportunities in the market. The growing number of strategic initiatives in China is expected to impact the market positively. For instance, in July 2023, Shanghai Fosun Pharmaceutical Co., Ltd received approval from the NMPA for its RT002 product to treat moderate to severe glabellar lines in adults. Moreover, in October 2023, Sinclair, a subsidiary of Huadong Medicine Co., Ltd. & ATGC Co., Ltd, announced a strategic collaboration and licensing agreement through which Sinclair shall develop and commercialize ATGC's BoNT-A, ATGC-110 for aesthetic and therapeutic indication.

China Botulinum Toxin Type A Market Report Highlights:

  • The upper face segment held the largest share of over 59.75% in 2023 and is anticipated to grow at the fastest CAGR over the forecast period owing to increasing demand for aesthetic treatments aimed at reducing wrinkles in areas, such as the forehead, glabella, and crow's feet
  • The females segment held the largest share of 85.01% as women in China often experience early signs of aging and skin dullness, influenced by hormonal fluctuations, such as declining estrogen levels. However, the male segment is anticipated to grow at the fastest CAGR of 23.2% during the forecast period due to changing societal patterns, greater willingness to undertake aesthetic treatments, and media influence regarding signs of aging
  • The 31 to 59 years age group segment held the largest share of over 64.1% in 2023. This age group is typically more concerned with signs of aging, such as wrinkles and fine lines, making botulinum toxin type A injections a popular choice for rejuvenating facial appearance
  • The MedSpas segment held the largest share of over 43.4% in 2023. These facilities offer increased accessibility and convenience, which boosts the growth
Product Code: GVR-4-68040-366-6

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Application
    • 1.2.2. Gender
    • 1.2.3. Age
    • 1.2.4. End Use
    • 1.2.5. Estimates and forecast timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity price analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Application Segment
    • 2.2.2. Gender Segment
    • 2.2.3. Age Segment
    • 2.2.4. End Use Segment
  • 2.3. Competitive Insights

Chapter 3. China Botulinum Toxin Type A Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing demand for aesthetic procedures
      • 3.2.1.2. Advancements in technology and techniques
      • 3.2.1.3. Rising disposable income
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Stringent Regulatory Policies
      • 3.2.2.2. Declining Number Of Aesthetic Practices
  • 3.3. China Botulinum Toxin Type A Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. China Botulinum Toxin Type A Market: Application Estimates & Trend Analysis

  • 4.1. China Botulinum Toxin Type A Market: Application Dashboard
  • 4.2. China Botulinum Toxin Type A Market: Application Movement Analysis
  • 4.3. China Botulinum Toxin Type A Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 4.4. Upper Face
    • 4.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 4.4.1.1. Glabellar Wrinkles
      • 4.4.1.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 4.4.1.2. Forehead Wrinkles
      • 4.4.1.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 4.4.1.3. Crow's Feet
      • 4.4.1.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.5. Mid Face
    • 4.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.6. Lower Face
    • 4.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.7. Body
    • 4.7.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. China Botulinum Toxin Type A Market: Gender Estimates & Trend Analysis

  • 5.1. China Botulinum Toxin Type A Market: Gender Dashboard
  • 5.2. China Botulinum Toxin Type A Market: Gender Movement Analysis
  • 5.3. China Botulinum Toxin Type A Market Size & Forecasts and Trend Analysis, by Gender, 2018 to 2030 (USD Million)
  • 5.4. Female
    • 5.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 5.5. Male
    • 5.5.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. China Botulinum Toxin Type A Market: Age Estimates & Trend Analysis

  • 6.1. China Botulinum Toxin Type A Market: Age Dashboard
  • 6.2. China Botulinum Toxin Type A Market: Age Movement Analysis
  • 6.3. China Botulinum Toxin Type A Market Size & Forecasts and Trend Analysis, by Age, 2018 to 2030 (USD Million)
  • 6.4. Below 30 Years
    • 6.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 6.5. 31 to 59 Years
    • 6.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 6.6. Over 60 Years
    • 6.6.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 7. China Botulinum Toxin Type A Market: End Use Estimates & Trend Analysis

  • 7.1. China Botulinum Toxin Type A Market: End Use Dashboard
  • 7.2. China Botulinum Toxin Type A Market: End Use Movement Analysis
  • 7.3. China Botulinum Toxin Type A Market Size & Forecasts and Trend Analysis, by End-use, 2018 to 2030 (USD Million)
  • 7.4. Hospitals
    • 7.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 7.5. Clinics & Aesthetic Centers
    • 7.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 7.6. Medspas
    • 7.6.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Manufacturers
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2023
    • 8.3.4. Hugel
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Medytox
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Daewoong
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Galderma
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Huons Global
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Pharma Research BIO
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. AbbVie
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Sinopharm Group
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Huadong Medicine
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives
    • 8.3.14. Merz Pharma.
      • 8.3.14.1. Company overview
      • 8.3.14.2. Financial performance
      • 8.3.14.3. Product benchmarking
      • 8.3.14.4. Strategic initiatives
Product Code: GVR-4-68040-366-6

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviation
  • Table 3. China botulinum toxin type a market, by application, 2018 - 2030 (USD Million)
  • Table 4. China botulinum toxin type a market, by gender, 2018 - 2030 (USD Million)
  • Table 5. China botulinum toxin type a market, by age, 2018 - 2030 (USD Million)
  • Table 6. China botulinum toxin type a market, by end-use, 2018 - 2030 (USD Million)
  • Table 7. Participant's overview
  • Table 8. Financial performance
  • Table 9. Key companies undergoing expansions
  • Table 10. Key companies undergoing acquisitions
  • Table 11. Key companies undergoing collaborations
  • Table 12. Key companies launching new products/services
  • Table 13. Key companies undergoing partnerships
  • Table 14. Key companies undertaking other strategies

List of Figures

  • Fig. 1 China botulinum toxin type A market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modelling for market share assessment
  • Fig. 8 China botulinum toxin type a market revenues, 2023, (USD Billions)
  • Fig. 9 Market driver relevance analysis (Current & future impact)
  • Fig. 10 Market restraint relevance analysis (Current & future impact)
  • Fig. 11 Porter's five forces analysis
  • Fig. 12 PESTLE analysis
  • Fig. 13 China botulinum toxin type A market: application outlook
  • Fig. 14 China upper face market, 2018 - 2030 (USD Billion)
  • Fig. 15 China glabellar wrinkles market, 2018 - 2030 (USD Billion)
  • Fig. 16 China forehead wrinkles market, 2018 - 2030 (USD Billion)
  • Fig. 17 China crow's feet market, 2018 - 2030 (USD Billion)
  • Fig. 18 China mid face market, 2018 - 2030 (USD Billion)
  • Fig. 19 China lower face market, 2018 - 2030 (USD Billion)
  • Fig. 20 China body market, 2018 - 2030 (USD Billion)
  • Fig. 21 China botulinum toxin type A market: gender movement analysis
  • Fig. 22 China female market, 2018 - 2030 (USD Billion)
  • Fig. 23 China male market, 2018 - 2030 (USD Billion)
  • Fig. 24 China botulinum toxin type A market: age outlook
  • Fig. 25 China below 30 years market, 2018 - 2030 (USD Billion)
  • Fig. 26 China 31 to 59 years market, 2018 - 2030 (USD Billion)
  • Fig. 27 China over 60 years market, 2018 - 2030 (USD Billion)
  • Fig. 28 China botulinum toxin type A market: end-use movement analysis
  • Fig. 29 China hospitals market, 2018 - 2030 (USD Billion)
  • Fig. 30 China clinics & aesthetic centers market, 2018 - 2030 (USD Billion)
  • Fig. 31 China medspas market, 2018 - 2030 (USD Billion)
  • Fig. 32 Segment dashboard
  • Fig. 33 Market participant categorization
  • Fig. 34 Strategy mapping
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!